Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis

Imagem de Miniatura
Arquivos
art_LIPHAUS_Increased_Soluble_Cytoplasmic_Bcl2_Protein_Serum_Levels_and_2018.PDF (1.35 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
J RHEUMATOL PUBL CO
Autores
KISS, Maria Helena B.
Citação
JOURNAL OF RHEUMATOLOGY, v.45, n.11, p.1577-1580, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. To evaluate soluble Fas antigen (sFas), sFas ligand (sFasL), soluble tumor necrosis factor-related apoptosis-inducing ligand, and soluble cytoplasmic Bcl-2 protein (sBcl-2) serum levels, Fas and Bcl-2 expressions in T and B lymphocytes and monocytes and relations with erythrocyte sedimentation rate, C-reactive protein (CRP), Childhood Myositis Assessment Scale, and manual muscle testing in juvenile dermatomyositis (JDM). Methods. Serum levels were determined by ELISA and peripheral cell expressions by flow cytometry for patients with JDM or juvenile idiopathic arthritis (JIA), and healthy controls. Results. Patients with JDM had increased sBcl-2, which correlated with CRP. Expression of Bcl-2 was increased and expression of Fas was decreased in CD3+, CD4+, and CD8+ T lymphocytes compared with JIA and/or healthy controls. Conclusion. Patients with JDM presented a unique apoptosis-related proteins profile, which may contribute to disease development.
Palavras-chave
APOPTOSIS, JUVENILE DERMATOMYOSITIS, SOLUBLE BCL-2, FASL AND TRAIL, LYMPHOCYTES, MONOCYTES
URI
https://observatorio.fm.usp.br/handle/OPI/30018
Referências
  1. Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929
  2. BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
  3. De Bleecker JL, 2001, ACTA NEUROPATHOL, V101, P572
  4. Falcini F, 1999, CLIN IMMUNOL, V93, P59, DOI 10.1006/clim.1999.4765
  5. Falcini F, 2000, CLIN EXP RHEUMATOL, V18, P643
  6. Huber AM, 2004, ARTHRITIS RHEUM, V50, P1595, DOI 10.1002/art.20179
  7. Liphaus BL, 2013, LUPUS, V22, P940, DOI 10.1177/0961203313496300
  8. Liphaus BL, 2006, CLIN DEV IMMUNOL, V13, P283, DOI 10.1080/17402520600877786
  9. Liphaus BL, 2017, CLIN RHEUMATOL, V36, P2847, DOI 10.1007/s10067-017-3615-8
  10. Liphaus BL, 2010, CLINICS, V65, P327, DOI 10.1590/S1807-59322010000300014
  11. Liphaus BL, 2007, J RHEUMATOL, V34, P1580
  12. Nozawa K, 1997, ARTHRITIS RHEUM, V40, P1126, DOI 10.1002/art.1780400617
  13. Petty RE, 2004, J RHEUMATOL, V31, P390
  14. Rider LG, 2010, ARTHRIT CARE RES, V62, P465, DOI 10.1002/acr.20035
  15. Sahin M, 2007, CLIN BIOCHEM, V40, P6, DOI 10.1016/j.clinbiochem.2006.09.003
  16. Sallum AME, 2009, CLIN EXP RHEUMATOL, V27, P519
  17. Sallum AME, 2006, AUTOIMMUN REV, V5, P93, DOI 10.1016/j.autrev.2005.05.008
  18. Sallum AME, 2002, ARQ NEURO-PSIQUIAT, V60, P889, DOI 10.1590/S0004-282X2002000600001
  19. Sugiura T, 1999, ARTHRITIS RHEUM, V42, P291, DOI 10.1002/1529-0131(199902)42:2<291::AID-ANR11>3.0.CO;2-1
  20. Zhao Y, 2007, CLIN IMMUNOL, V125, P165, DOI 10.1016/j.clim.2007.06.011

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/17
Carregar mais